Ketamine in Modern Medicine: Antidepressant Breakthrough, Anesthetic Staple, or Substance of Misuse

Ketamine, originally synthesized in the early 1960s as a safer alternative to phencyclidine (PCP), has since evolved into a multifaceted agent with applications extending far beyond its initial use as a dissociative anesthetic in surgical settings. With a unique pharmacological profile characterized by N-methyl-D-aspartate (NMDA) receptor antagonism, ketamine induces rapid anesthesia, analgesia, and dissociation. However, over the past two decades, it has garnered significant attention for its rapid-acting antidepressant effects, particularly in individuals with treatment-resistant depression (TRD), a condition that fails to respond to conventional antidepressants. Clinical trials and real-world data have demonstrated that low-dose ketamine, administered intravenously or intranasally, can produce profound and sustained improvements in mood within hours, a stark contrast to the delayed onset of traditional antidepressants.The therapeutic promise of ketamine has extended into the realms of post-traumatic stress disorder (PTSD), bipolar depression, anxiety disorders, and suicidal ideation, positioning it as a breakthrough in psychiatric medicine. Nevertheless, ketamine’s benefits are tempered by concerns surrounding its safety, potential for abuse, and long-term neuropsychiatric effects. As a Schedule III controlled substance, ketamine is also misused recreationally, known colloquially as “Special K,” for its hallucinogenic and dissociative properties. Chronic use has been associated with cognitive deficits, urinary tract dysfunction, and addiction, necessitating careful monitoring in both clinical and non-clinical contexts.This review paper provides a comprehensive examination of ketamine’s evolving role in modern medicine by exploring its pharmacodynamics and pharmacokinetics, mechanisms of antidepressant action, and evidence from clinical studies. It also delves into its misuse potential, societal impact, ethical considerations in off-label psychiatric use, and regulatory challenges. By synthesizing data from preclinical and clinical research, the paper seeks to present a balanced perspective on ketamine’s dual identity—as a therapeutic breakthrough and a drug of misuse—highlighting the imperative for responsible clinical integration and ongoing research.